An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 022252
Company: BAYER HLTHCARE

Summary Review

Products on NDA 022252

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
NATAZIA	DIENOGEST; ESTRADIOL VALERATE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	TABLET;ORAL	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 022252

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/14/2012	ORIG-2	Approval	Efficacy	STANDARD	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022252s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022252Orig2s000ltr.pdf
05/06/2010	ORIG-1	Approval	Type 1 - New Molecular Entity and Type 4 - New Combination	STANDARD	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022252s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022252s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/26/2024	SUPPL-9	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022252s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022252Orig1s009ltr.pdf
04/29/2022	SUPPL-7	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022252s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022252Orig1s007ltr.pdf
08/21/2015	SUPPL-4	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022252Orig1s004ltr.pdf
08/22/2013	SUPPL-3	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022252s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022252Orig1s003ltr.pdf
02/13/2012	SUPPL-1	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022252s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022252s001ltr.pdf

Labels for NDA 022252

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/26/2024	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022252s009lbl.pdf
04/29/2022	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022252s007lbl.pdf
08/21/2015	SUPPL-4	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf
08/22/2013	SUPPL-3	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022252s003lbl.pdf
03/14/2012	ORIG-2	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022252s002lbl.pdf
02/13/2012	SUPPL-1	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022252s001lbl.pdf
05/06/2010	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022252s000lbl.pdf

Top